Imputation of Variants from the 1000 Genomes Project Modestly Improves Known Associations and Can Identify Low-frequency Variant - Phenotype Associations Undetected by HapMap Based Imputation

Andrew R. Wood1, John R. B. Perry1,2,3, Toshiko Tanaka4, Dena G. Hernandez5,6, Hou-Feng Zheng7, David Melzer8, J. Raphael Gibbs5,6, Michael A. Nalls5, Michael N. Weedon1, Tim D. Spector3, J. Brent Richards3,7, Stefania Bandinelli5,10, Luigi Ferrucci6, Andrew B. Singleton5, Timothy M. Frayling1*

1 Genetics of Complex traits, Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom, 2 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 3 Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom, 4 Longitudinal Studies Section, Clinical Research Branch, Gerontology Research Center, National Institute on Aging, Baltimore, Maryland, United States of America, 5 Laboratory of Neurogenetics, National Institute of Aging, Bethesda, Maryland, United States of America, 6 Department of Molecular Neuroscience and Reta Ilana Laboratories, Institute of Neurology, UCL, London, United Kingdom, 7 Departments of Medicine, Human Genetics, Epidemiology and Biostatistics, Jewish General Hospital, McGill University, Montreal, Quebec, Canada, 8 Epidemiology and Public Health, Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom, 9 Tuscan Regional Health Agency, Florence, Italy, I.O.T. and Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy, 10 Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy

Abstract

Genome-wide association (GWA) studies have been limited by the reliance on common variants present on microarrays or imputable from the HapMap Project data. More recently, the completion of the 1000 Genomes Project has provided variant and haplotype information for several million variants derived from sequencing over 1,000 individuals. To help understand the extent to which more variants (including low frequency (1% ≤ MAF <5%) and rare variants (<1%)) can enhance previously identified associations and identify novel loci, we selected 93 quantitative circulating factors where data was available from the InCHIANTI population study. These phenotypes included cytokines, binding proteins, hormones, vitamins and ions. We selected these phenotypes because many have known strong genetic associations and are potentially important to help understand disease processes. We performed a genome-wide scan for these 93 phenotypes in InCHIANTI. We identified 21 signals and 33 signals that reached P<5 × 10⁻⁵ based on HapMap and 1000 Genomes imputation, respectively, and 9 and 11 that reached a stricter, likely conservative, threshold of P<3 × 10⁻¹¹ respectively. Imputation of 1000 Genomes genotype data modestly improved the strength of known associations. Of 20 associations detected at P<5 × 10⁻⁸ in both analyses (17 of which represent well replicated signals in the NHGRI catalogue), six were captured by the same index SNP, five were nominally more strongly associated in 1000 Genomes imputed data and one was nominally more strongly associated in HapMap imputed data. We also detected an association between a low frequency variant and phenotype that was previously missed by HapMap based imputation approaches. An association between rs112635299 and alpha-1 globulin near the SERPINA gene represented the known association between rs28929474 (MAF = 0.007) and alpha1-antitrypsin that predisposes to emphysema (P=2.5×10⁻¹²). Our data provide important proof of principle that 1000 Genomes imputation will detect novel, low frequency-large effect associations.

Introduction

Genome-wide association (GWA) studies have identified many novel associations between common genetic variants and human traits. These studies capture a large proportion of SNP-based common variation in the human genome but are less efficient at capturing low frequency and rare variants.

Imputation is the process of inferring missing data based on known data [1]. Imputation is useful for performing GWA meta-analyses across studies with the same traits but different genotyping arrays. Imputation can also potentially identify signals of association not detected by direct genotypes. In the simplest scenario, a causal variant, or the most strongly associated genetic variant, may not be directly genotyped and may exist on a haplotype that is optimally captured by two rather than one directly genotyped SNP (Figure 1).
Table 1. Basic characteristics of the 1210 InCHIANTI subjects at baseline.

| Characteristic                  | Mean (Range) or% |
|---------------------------------|------------------|
| Age (years)                     | 68.2 (21–102)    |
| Sex (% male)                    | 44.6%            |
| BMI                             | 27.2 (18–46.6)   |
| Current smokers (% case)        | 18.8%            |
| History of hypertension (% case)| 38.4%            |
| Treatment for hypertension:     |                  |
| - former and current (% case)   | 30.1%            |
| History of diabetes (% case)    | 9.5%             |
| Treatment for diabetes:         |                  |
| - former and current (% case)   | 6.58%            |
| History of myocardial infarction(% case) | 3.6% | |
| Treatment for myocardial infarction: |            |
| - former and current (% case)   | 2.0%             |

There are now two main sources of reference genotypes for imputation of missing variants. The International HapMap Project Phases 1 to 3 [2–5] consists of 4.1 million directly genotyped SNPs in 1,486 individuals and has facilitated the imputation of approximately 2.5 million SNPs in standard GWA studies. More recently, the 1000 Genomes Project has completed the low-pass sequencing of the whole genome from 1,094 individuals from a range of ethnic groups [6]. The project has annotated >37 million variants. The sequencing based approach and the large number of individuals means these variants include many low frequency (1% ≤ MAF <5%) and rare (MAF <1%) variants.

In this study we tested the hypothesis that imputation of variants identified by the 1000 Genomes Project (including low frequency and rare variants) would enhance previously identified associations and identify novel associations. We selected 93 traits measured in ~1,200 individuals in the InCHIANTI study (Table 1 and Table S1). All traits were continuous measures of circulating factors [7], [8]. These traits included circulating lipids, proteins, ions and vitamins and were selected for two reasons. First, for many traits, strong genetic associations have previously been observed in relatively small sample sizes, and so we potentially had good power to detect novel effects and stronger signals at known loci. These signals include those far exceeding genome-wide significance in our dataset alone and therefore offer a good opportunity to assess whether or not 1000 Genomes imputation can improve and refine known associations. Second, identifying genetic associations with circulating factors is potentially important to help understand disease processes. Many circulating factors are altered in disease cases compared to controls, but it is rarely understood if these factors are causal, confounded or secondary to disease processes. Genetic variants can be used to help identify causal pathways using Mendelian randomisation [9–12].

Results

Variation captured by HapMap and 1000 Genomes

After applying quality control metrics we captured $2,493,682$ and $10,879,115$ SNPs from HapMap (release 22) and 1000 Genomes imputation (November 2010, Phase1–a), respectively (Table S2, Figure S1).

The 1000 Genomes based imputation captured many more variants at high quality (defined as $r^2_{imp} > 0.3$ in HapMap imputation and $r^2_{imp} > 0.5$ in 1000 Genomes imputation) compared to the HapMap based imputation (Figure 2).

We captured $2,172,804$ and $5,737,929$ common SNPs (MAF≥5%) based on HapMap and 1000 Genomes based imputation, respectively. For low frequency variants (1% ≤ MAF <5%) we captured 274,995 and 1,953,185 based on HapMap and 1000 Genomes imputation respectively. For rare variants (MAF<1%) we captured 45,883 and 3,188,001 rare SNPs based on the HapMap and 1000 Genomes based imputation, respectively.

Identification of association signals using HapMap and 1000 Genomes Imputation

Associations identified by HapMap imputation. Using HapMap based imputation we identified 21 signals of association at $P<5\times10^{-8}$ including 19 circulating factors (Table 2). Nine of these signals reached the stricter statistical threshold of $P<5\times10^{-11}$. Of these 21 signals, 14 were known, based on the same or an $r^2>0.8$ proxy to our index SNP reaching $P<5\times10^{-8}$.
Figure 2. Distributions of imputation quality ($r^2$) across different minor allele frequency (MAF) bins. Note differences in Y axes scales. doi:10.1371/journal.pone.0064343.g002
Table 2. Associations of circulating factors based on HapMap imputation ordered by minor allele frequency group (<5% or ≥5), chromosome and base-pair position.

| Trait                          | GC  | Chr | SNP            | BP (b37) | MAF       | P*        | Nearest Gene | Annotation |
|-------------------------------|-----|-----|----------------|----------|-----------|-----------|--------------|------------|
| Alkaline phosphatase         | 1.055 | 12  | rs1880889      | 41721235 | 0.03      | 1.96E-08  | P2ZRN4       | Known      |
| Homocysteine                  | 1.043 | 1   | rs1801133      | 11856378 | 0.495     | 1.75E-11  | MTHFR        | Known      |
| Vitamin B6                   | 1.017 | 1   | rs4654748      | 21786068 | 0.499     | 8.84E-09  | NBPF3        | Known      |
| Interleukin-6R               | 1.134 | 1   | rs8192284      | 154426970| 0.385     | 3.60E-53  | IL6R         | Known      |
| C-reactive protein           | 1.035 | 1   | rs12741825     | 159670145| 0.301     | 1.08E-08  | CRP          | Known      |
| Oxidized LDL                 | 1.029 | 2   | rs676210       | 21231524 | 0.239     | 4.05E-30  | APOB         | Known (other trait) |
| Macrophage inflammatory protein-1b | 1.016 | 3   | rs1500004      | 46150937 | 0.104     | 2.06E-08  | XCR1/CCR1    | Novel      |
| Lipoprotein a                | 1.057 | 6   | rs10455872     | 161010181| 0.056     | 1.18E-20  | LPA          | Known      |
| Insulin-like growth factor bp-3| 1.038 | 7   | rs10260816     | 46010100 | 0.456     | 4.42E-14  | IGFBP3       | Known      |
| 90K Protein                  | 1.016 | 8   | rs406652       | 16042507 | 0.159     | 1.56E-09  | MSR1         | Novel      |
| Interleukin-18               | 1.047 | 11  | rs2250417      | 112085316| 0.44      | 2.94E-14  | BCO2         | Known      |
| Vitamin E alpha tocopherol   | 1.066 | 11  | rs964184       | 116648917| 0.125     | 1.33E-08  | ZNF259       | Known      |
| Triglycerides                | 1.052 | 11  | rs964184       | 116648917| 0.152     | 9.03E-09  | ZNF259       | Known      |
| Soluble transferrin receptor | 1.04  | 11  | rs1242229      | 117062370| 0.129     | 6.55E-09  | SDF2         | Known      |
| HDL cholesterol              | 1.033 | 16  | rs1800775      | 56995236 | 0.486     | 8.01E-13  | CETP         | Known      |
| Alpha-2-globulin (%)         | 1.058 | 16  | rs2000999      | 72108093 | 0.228     | 2.13E-08  | HPR          | Known (other trait) |
| Lutein                       | 1.026 | 16  | rs11645428     | 81258896 | 0.468     | 1.17E-13  | PKD1L2       | Known      |
| Beta carotene                | 1.051 | 16  | rs6564851      | 81624597 | 0.364     | 1.70E-10  | PKD1L2/BCMO1 | Known      |
| Free thyroxine (FT4)         | 1.03  | 17  | rs7212734      | 63404660 | 0.444     | 1.10E-08  | AIPL1        | Novel      |
| Macrophage inflammatory protein-1b | 1.016 | 17  | rs1015673      | 34477386 | 0.443     | 1.25E-22  | TBCD138      | Known      |
| Vitamin E alpha tocopherol   | 1.066 | 19  | rs10401969     | 19407718 | 0.057     | 9.32E-09  | SUGP1        | Known (other trait) |

GC = genotypic control factor used to adjust P-value, Chr = chromosome, BP (b37) = human genome build 37 base pair position, SNP = index SNP representing signal, MAF = minor allele frequency, P* = P-value derived after applying genomic control.

Annotations refer to whether associations represent known (present in NHGRI GWAS catalogue) signals or loci or with others in published GWA studies with the same or very similar trait.

A further 3 signals were classified as known signals but with different traits. A signal near the HPR gene was associated with alpha-2 globulin and was previously reported as associated with haptoglobin. A signal near the APOB gene was associated with oxidized LDL and was previously associated with HDL and triglycerides, and a signal near the SUGP1 gene was associated with vitamin E and was previously associated with LDL cholesterol, total cholesterol and triglycerides.

Of the remaining 4 signals, 3 were putative novel associations (Table 2), and one was an association with hsCRP and represented a previously known locus – our index SNP was correlated with an r² of 0.32 with a published hsCRP associated variant (rs876537 [13]) ~7 kb upstream of the CRP gene.

Association identified by 1000 Genomes imputation. Using 1000 Genomes based imputation we identified 33 signals of association at P<5×10⁻⁶ across 30 circulating factors (Table 3). Eleven of these signals reached a stricter statistical threshold of P<5×10⁻¹¹. These 33 signals included 14 of the 21 identified by HapMap based imputation (r² between Index HapMap and index 1000 Genomes SNP >0.8 of which 6 were the same lead SNP in both analyses) and 6 signals that represented the same loci as detected by HapMap based imputation (0.2<r²<0.8 between the 1000 Genomes and HapMap index SNPs) (Table 4). There was one HapMap based signal of association not detected by 1000 Genomes based imputation – rs12741825 representing CRP which did not reach genome-wide significance having passed 1000 Genomes imputation quality control (P=1.2×10⁻⁵, P_imp >0.99).

Of the 13 signals of association detected by 1000 Genomes imputation that were not detected by HapMap imputation (at P<5×10⁻⁶) in our study (Table 5), eight represented putative novel signals. The remaining five signals represented known loci (0.2<r²<0.8 with index SNPs in NHGRI GWAS catalogue). Plots of six of the 22 associations detected at P<5×10⁻⁶ in the 1000 genomes imputation analysis and that represent previously known signals or loci (r²>0.2 with SNPs in the NHGRI GWAS catalogue) are shown in Figure 3 and Figure 4.

Known and putative novel signals identified by 1000 Genomes that were missed by imputation with Hapmap.

For the 13 signals detected by the 1000 Genomes imputation but not by the HapMap imputation analysis, we calculated linkage disequilibrium between the index 1000 Genomes SNP and the most strongly associated HapMap SNPs within a 2 Mb window centred on the 1000 Genomes SNP (Table 5). One of the 13 signals of association was present in the HapMap data with a proxy SNP at r²>0.8, four with a proxy SNP at 0.5<r²<0.8 and one with a proxy SNP at r²≤0.2. As expected, HapMap associations for these six signals were close to genome-wide significance (P=1.2×10⁻⁵ to 7.9×10⁻⁶).

The remaining 7 signals detected in the 1000 Genomes imputation analyses but not by the HapMap based analysis
associated with other traits that are known or novel (Table S1), including common risk factors for heart disease.

**Table 5.** Genome-wide significant associations of circulating factors based on 1000 Genomes imputation ordered by minor allele frequency group (<5% or ≥5%), chromosome and base-pair position.

| Trait                  | GC  | Chr | SNP          | BP (b37) | MAF   | P**   | Nearest Gene | Annotation |
|------------------------|-----|-----|--------------|----------|-------|-------|--------------|------------|
| Total cholesterol      | 1.049 | 1   | rs116435220  | 46890686 | 0.011 | 2.18E-08 | FAAH        | Novel      |
| Tumor necrosis factor-a| 1.024 | 2   | rs188141385  | 14975369 | 0.004 | 4.16E-10 | FAM84A      | Novel      |
| Beta globulins (%)     | 1.034 | 4   | rs28645201   | 91528927 | 0.02  | 1.22E-09 | FAM190A     | Novel      |
| Vitamin B12            | 1.055 | 5   | rs146226203  | 150185826 | 0.012 | 3.01E-08 | CSDF62/IRGM | Novel      |
| Lipoprotein a           | 1.057 | 6   | rs55730499   | 161005610 | 0.048 | 3.43E-25 | LPA         | Known      |
| Cortisol/DHEAS ratio   | 1.007 | 7   | rs34670419   | 99130834 | 0.028 | 2.35E-08 | ZKSCAN5     | Known      |
| Dehydroepiandrosterone | 1.023 | 7   | rs34670419   | 99130834 | 0.028 | 2.07E-09 | ZKSCAN5     | Known      |
| Cl-                    | 1.075 | 7   | rs2371549    | 144172841 | 0.055 | 5.38E-09 | TPK1        | Novel      |
| Alkaline phosphatase   | 1.055 | 12  | rs1880889    | 41721235 | 0.029 | 3.08E-08 | PDZRN4      | Known      |
| Alpha-1 globulin (%)   | 1.054 | 14  | rs112635299  | 94838142 | 0.007 | 2.51E-12 | SERPINAI1   | Novel      |
| Alpha-2 globulin (%)   | 1.058 | 17  | rs181929163  | 6340545  | 0.01  | 1.57E-08 | CEPI12      | Known      |
| Homocysteine           | 1.043 | 1   | rs1801133    | 11856378 | 0.497 | 2.01E-11 | MTHFR       | Known      |
| Vitamin B6             | 1.017 | 1   | rs4654932    | 2109436  | 0.417 | 7.39E-09 | NBPB3       | Known      |
| Interleukin-6R         | 1.134 | 1   | rs12730935   | 154419682 | 0.377 | 2.28E-03 | IL6R        | Known      |
| Oxidized LDL           | 1.029 | 2   | rs767210     | 21231524 | 0.239 | 4.12E-30 | APOB        | Known      |
| Macrophage inflammatory protein-1b* | 1.016 | 3   | rs11341849   | 46384204 | 0.09  | 2.14E-11 | CCR2        | Novel      |
| Insulin-like growth factor bp-3 | 1.038 | 7   | rs71550311   | 45867430 | 0.459 | 1.39E-14 | IGBP3       | Novel      |
| 90K Protein*           | 1.016 | 8   | rs28491438   | 16050871 | 0.148 | 6.03E-10 | MSR1        | Novel      |
| Beta Cryptoxanthin     | 1.021 | 8   | rs75226183   | 77295977 | 0.087 | 1.69E-09 | LOC10019237 | Novel      |
| Creatine phosphokinase | 1.029 | 10  | rs6817100    | 10182621 | 0.28  | 4.18E-08 | CPN1        | Known      |
| Interleukin-18         | 1.047 | 11  | rs2250417    | 112085316 | 0.44  | 2.97E-14 | BCO2        | Known      |
| Vitamin E alpha tocopherol | 1.066 | 11  | rs964184     | 116648917 | 0.151 | 6.66E-09 | ZNF259      | Known      |
| Triglycerides          | 1.052 | 11  | rs964184     | 116648917 | 0.151 | 1.01E-08 | ZNF259      | Known      |
| Soluble transferrin receptor | 1.04  | 11  | rs7940310    | 117024481 | 0.13  | 7.17E-09 | PAFAH1B2    | Known      |
| HDL cholesterol        | 1.033 | 16  | rs711752     | 56996211 | 0.436 | 8.32E-13 | CETP        | Known      |
| Alpha-2 globulin (%)   | 1.058 | 16  | rs2287997    | 72140553 | 0.227 | 1.45E-10 | DHX38       | Known      |
| Beta carotene          | 1.051 | 16  | rs12926540   | 81258987 | 0.362 | 6.98E-11 | PKD1L2/BCMO1 | Known     |
| Lutein                | 1.026 | 16  | rs9708919    | 81260786 | 0.391 | 7.84E-14 | PKD1L2/BCMO1 | Known     |
| Free thyroxine (FT4)*  | 1.032 | 17  | rs58926603   | 6341870  | 0.393 | 5.62E-09 | APLI/FAM64A | Novel      |
| Macrophage inflammatory protein-1b | 1.016 | 17  | rs4796217    | 34819191 | 0.345 | 6.62E-21 | TBC1D3G     | Known      |
| Vitamin E alpha tocopherol | 1.066 | 19  | rs58542926   | 19379549 | 0.064 | 1.18E-08 | TM6SF2      | Known      |
| LDL cholesterol        | 1.041 | 19  | rs1065853    | 45413233 | 0.075 | 1.76E-09 | APOE        | Known      |
| Gamma-glutamytransferase | 1.043 | 22  | rs2006227    | 24995756 | 0.386 | 1.70E-08 | GGT1        | Known      |

* = associations that represent novel signals in both HapMap and 1000 Genomes-based analyses, $P^{**} = P$-value derived after applying genomic control.

doi:10.1371/journal.pone.0064343.t003

appeared to represent signals specifically detected by 1000 Genomes imputation. These seven signals had very low correlations ($r^2<0.05$) with the most strongly associated HapMap SNP (Table 5). Six of these seven signals represented putative low frequency – large effect variants, with minor allele frequencies ≤ 0.02 and per allele effect sizes of 1.1 – 2.1 standard deviations (SDs). We therefore examined these loci in more detail. We checked imputed dosages and trait values for the small number of heterozygous individuals that were driving these associations, but found no obvious sources of error (Figure S2). All but one of these 7 signals had a proxy SNP that also showed strong evidence of association, even if the association did not reach $P<5\times10^{-8}$.

Does 1000 Genomes imputation identify stronger associations at loci identified by HapMap based imputation?

We identified 14 loci associated with 13 traits where both the HapMap and 1000 Genomes index SNPs were $P<5\times10^{-8}$ and differed from each other (Table 4 and Table 6). In the multivariable SNP analyses that included the two SNPs at each locus against the relevant phenotype, the 1000 Genomes SNP was more strongly associated in 13 of 14 loci (one-tail Binomial $P=0.0009$). The $P$-value improvements were marginal for 8 of these associations and the 1000 genomes signal was not statistically stronger, but 5 of the 14 associations, showed evidence of stronger signals at $P<0.05$ and three at $P<0.01$, Table 6).
Replication and validation

For three of the putative novel associations we attempted to replicate associations in additional data. We used 476 and 529 individuals from the BLSA study to test associations with TNF-alpha and vitamin B12, respectively, and 232, 1554 and 406 individuals from the TwinsUK study to test associations with TNF-alpha and vitamin B12, respectively. We did not find any evidence of association. However, one of the putative novel variants does represent a real association. On closer inspection of the literature and comparison of linkage disequilibrium statistics we showed that the SNP rs112635299 represents the known signal between an amino acid changing variant in the SERPINA gene and alpha-1-globulin [14]. This signal is present in our data at a 0.007 MAF, is a strong risk factor for the lung disease emphysema and was missed by imputation of HapMap genotypes (the SNP identified is not present in the HapMap reference panel, best P-value in the region 2×10^{-4}) (Table 7 and Figure 5).

Discussion

Our results show that imputation of genotype data from the sequenced based 1000 Genomes reference panel improves our ability to detect genotype-phenotype associations compared to the microarray-genotype based HapMap reference panel. Our results provide two main conclusions. First, that imputation of 1000 Genomes genotype data marginally improves the strength of association signals at known loci. Of 20 associations detected at P<5×10^{-5} in both analyses (17 of which represent well replicated signals in the NHGRI catalogue), six were captured by the same index SNP, five were more strongly associated in HapMap imputed data and one was nominally more strongly associated in 1000 Genomes imputed data (based on multivariable statistics Table 6). This result was not surprising given that most known associations involve common variants that are likely to be well imputed by both reference datasets. Nevertheless, it is possible that associations undetected by HapMap can be appreciably stronger when using 1000 Genomes imputation, as previously reported in ase-QTL data [15]. We also detected previously unreported associations between known signals and traits. The signals between variants near SUGPI/TM6SF2 and vitamin E and APOB and oxidised LDL were both previously reported with triglycerides and LDL cholesterol. Vitamin E is a lipid-soluble vitamin and associations between lipid variants and vitamin levels have been described before [16].

The second main conclusion is that imputation from 1000 Genomes data can detect associations between low frequency variants and phenotypes that were previously missed by HapMap based imputation approaches. The association between rs112635299 and alpha-1 globulin (%) near the SERPINA gene represents the same signal as that detected between rs28929474.

### Table 4. The 20 signals and loci found in both HapMap and 1000 Genomes ordered by minor allele frequency group (<5% or ≥5%) and chromosome.

| Trait | Chr | HapMap-based Analysis | 1000 Genomes-based Analysis | BP Dist. | LD (r²) |
|-------|-----|-----------------------|-----------------------------|----------|---------|
|       | SNP | MAF | P* | SNP | MAF | P* |
| Alkaline Phosphatase | 12 | rs1880889 | 0.03 | 1.96E-08 | rs1880889 | 0.029 | 3.08E-08 | – | – |
| Interleukin-6R | 1 | rs8192284 | 0.385 | 3.60E-53 | rs12730935 | 0.377 | 2.28E-53 | 7078 | 0.957 |
| Homocysteine | 1 | rs1801133 | 0.495 | 1.75E-11 | rs1801133 | 0.497 | 2.01E-11 | – | – |
| Vitamin B6 | 1 | rs4654748 | 0.499 | 8.84E-09 | rs4654932 | 0.417 | 7.39E-09 | 23368 | 0.744 |
| Oxidized LDL | 2 | rs676210 | 0.239 | 4.05E-30 | rs676210 | 0.239 | 4.12E-30 | – | – |
| Macrophage inflammatory protein-1b | 3 | rs1500004 | 0.104 | 2.60E-08 | rs113341849 | 0.09 | 2.14E-11 | 233267 | 0.667 |
| Lipoprotein a | 6 | rs10455872 | 0.056 | 1.18E-20 | rs55730499 | 0.048 | 3.43E-25 | 4508 | 0.888 |
| Insulin-like growth factor bp-3 | 7 | rs10260816 | 0.456 | 4.42E-14 | rs71553011 | 0.459 | 1.39E-14 | 22670 | 0.871 |
| 90K Protein | 8 | rs406652 | 0.159 | 1.56E-09 | rs28491433 | 0.148 | 6.03E-10 | 8364 | 0.932 |
| Soluble transferrin receptor | 11 | rs1242229 | 0.129 | 6.55E-09 | rs7940310 | 0.13 | 7.17E-09 | 37889 | 0.956 |
| Triglycerides | 11 | rs964184 | 0.152 | 9.30E-09 | rs964184 | 0.151 | 1.01E-08 | – | – |
| Lipid alpha tocopherol | 11 | rs964184 | 0.152 | 1.33E-08 | rs964184 | 0.151 | 6.66E-09 | – | – |
| Interleukin-18 | 11 | rs2250417 | 0.44 | 2.94E-14 | rs2250417 | 0.44 | 2.97E-14 | – | – |
| Alpha-2 globulin (%) | 16 | rs2009999 | 0.228 | 2.13E-08 | rs2287977 | 0.227 | 1.45E-10 | 32460 | 0.937 |
| Beta Carotene | 16 | rs6568451 | 0.364 | 1.70E-10 | rs12926540 | 0.362 | 6.98E-11 | 5610 | 0.954 |
| Lutein | 16 | rs11464542 | 0.468 | 1.17E-13 | rs9708919 | 0.391 | 7.84E-14 | 1890 | 0.53 |
| HDL cholesterol | 16 | rs1800775 | 0.486 | 8.01E-13 | rs711752 | 0.436 | 8.32E-13 | 975 | 0.774 |
| Macrophage inflammatory protein-1b | 17 | rs1015673 | 0.129 | 6.55E-09 | rs7940310 | 0.13 | 7.17E-09 | 37889 | 0.956 |
| Free thyroxine (FT4) | 17 | rs7212734 | 0.444 | 1.0E-08 | rs58926603 | 0.393 | 5.62E-09 | 1410 | 0.547 |
| Vitamin E alpha tocopherol | 19 | rs10401969 | 0.057 | 9.32E-09 | rs58542926 | 0.064 | 1.18E-08 | 28169 | 1 |

SNP = index SNP representing signal, MAF = minor allele frequency, P* = P-value derived after applying genomic control correction, BP Dist. = base pair distance between the HapMap and 1000 Genomes index SNPs, LD (r²) = linkage disequilibrium measure based on r² correlation.

Fourteen associations represent the same signals (r²>0.8) of which 6 are represented by the same index SNP. The remaining 6 represent the same locus (0.2<r²<0.8).

doi:10.1371/journal.pone.0064343.t004
Figure 3. Locus zoom plots of 6 loci reaching $p < 5 \times 10^{-8}$ in both the HapMap- and the 1000 Genomes imputed data and that represent known associations ($r^2 > 0.2$ in the NHGRI GWAS catalogue).

doi:10.1371/journal.pone.0064343.g003
(MAF = 0.007; \( r^2 = 0.38 \)) and alpha-1-antitrypsin that predisposes to emphysema [14]. Although previously known, this association provides important proof of principle that 1000 Genomes imputation can detect novel, low frequency-large effect associations, and potentially save costs of sequencing within studies. One additional association reached our stricter cut-off of \( P<5 \times 10^{-11} \) in 1000 Genomes based imputation that was not previously reported. Although we have no replication data, the signal between rs113341849 near the CCR1 and CCR2 genes and Macrophage inflammatory protein-1b is likely to be real given that these genes encode the receptors to which the MIP1b proteins bind.

A third point emerging from our data is that the selection of appropriate statistical thresholds is important when testing more than one trait and many more variants. Of three putative low-frequency-large effect signals we were able to follow up in additional samples none showed evidence of replication. We note that 7 of the 8 putative low frequency-large effect novel associations identified in the 1000 Genomes based data did not reach our stricter cut-off of \( P<5 \times 10^{-11} \), and suspect that most represent false positives due to multiple testing.

The main strength of our study was that we tested a large number of circulating biomarkers. Of these phenotypes, 20 had known signals for the same trait, detectable at genome-wide significance in our single study of 1210 individuals. This large number of phenotypes allowed us to test the extent to which 1000 Genomes imputation enhances known association signals. One limitation to our study is the relatively small sample size. Imputation from the 1000 Genomes reference panel may be a limitation to our study is the relatively small sample size. Although we have no replication data, the signal between rs113341849 near the CCR1 and CCR2 genes and Macrophage inflammatory protein-1b is likely to be real given that these genes encode the receptors to which the MIP1b proteins bind.

A third point emerging from our data is that the selection of appropriate statistical thresholds is important when testing more than one trait and many more variants. Of three putative low-frequency-large effect signals we were able to follow up in additional samples none showed evidence of replication. We note that 7 of the 8 putative low frequency-large effect novel associations identified in the 1000 Genomes based data did not reach our stricter cut-off of \( P<5 \times 10^{-11} \), and suspect that most represent false positives due to multiple testing.

The main strength of our study was that we tested a large number of circulating biomarkers. Of these phenotypes, 20 had known signals for the same trait, detectable at genome-wide significance in our single study of 1210 individuals. This large number of phenotypes allowed us to test the extent to which 1000 Genomes imputation enhances known association signals. One limitation to our study is the relatively small sample size. Imputation from the 1000 Genomes reference panel may be a limitation to our study is the relatively small sample size. Although we have no replication data, the signal between rs113341849 near the CCR1 and CCR2 genes and Macrophage inflammatory protein-1b is likely to be real given that these genes encode the receptors to which the MIP1b proteins bind.

Methods

Samples

We used DNA from 1,210 individuals from the population based InCHIANTI study; a study of aging from the Chianti region in Tuscany, Italy [7], [8] (Table 1). All summary statistics based association data is available on request from the authors or from the InCHIANTI study door website at http://www.inchiantistudy.net/.

Phenotypes

We selected 93 circulating factors measured in the InCHIANTI study (Table S1). These circulating factors included lipids, proteins, (including binding proteins and hormones), vitamins and ions.

Genotyping and Imputation

 genome-wide genotyping was performed using the Illumina Infinium HumanHap550 genotyping chip. Standard quality control procedures were used to exclude individuals with discordant sex and call rates less than 98% and filter out SNPs with MAF <1%, Hardy Weinberg \( P<1 \times 10^{-4} \) and a call rate <99% [8]. There were no ethnic outliers based on a principle components analysis [8]. This resulted in data from 493,343 directly genotyped SNPs in 1,210 individuals. These 493,343 SNPs were used as the scaffold for HapMap and 1000 Genomes based imputation.

For HapMap based imputation we used MACH 1.0.16 to impute missing genotypes not captured by the Illumina chip. We used the HapMap r22 build-36 reference panel (CEU) and imputed 2,543,887 SNPs. The reference panel comprised of 120 haplotypes from 60 parents of 30 Caucasian trios. Of these 2,543,887 SNPs, we excluded 50,205 that were imputed with an \( r^2_{imp}<0.3 \) (a measure of imputation quality). This left 2,493,682 SNPs for association analyses.

To perform 1000 Genomes based imputation we estimated phase of contiguous variants in the InCHIANTI subjects using the haplotypes calculated using data from the 1000 Genomes Project consisting of 1,094 individuals and 2,188 haplotypes and the program MACH 1.0.16. We then imputed the variants in the build-37 November 2010 release of 1000 Genomes (Phase 1-\( \alpha \) interim) into the phased haplotypes using MINIMAC. This resulted in 37,426,735 imputed SNPs. Of these 37,426,735 SNPs, we excluded 26,547,618 that were imputed with an \( r^2_{imp}<0.5 \). We used a more stringent cut-off for 1000 Genomes imputation as recommended at time of analysis. This left 10,879,115 SNPs for association analyses. We used a multi-ethnic reference panel that included 301 Europeans (including 98 Tuscans), 181 Americans, 246 Africans and 286 Asians in an attempt to capture variants that may be rare in Europeans but more common on haplotypes from different ethnic backgrounds.

Association analysis

Each phenotype measured at baseline was inverse normalised before age and sex adjusted residuals were generated. A second inverse-normalisation was subsequently applied to the residuals. We ran genome-wide association analysis using MACH2QTL for each trait using both HapMap and 1000 Genomes imputed datasets. We performed a univariable test with dosages representing the index HapMap or index 1000 Genomes SNP as independent variables in an additive genetic model and the normalized residuals of the relevant phenotypes as dependent variables in a linear regression analysis.

Linkage disequilibrium estimates

We estimated linkage disequilibrium within the InCHIANTI data. We used 1000 Genomes imputed dosages (except for two SNPs, where we used HapMap-based dosages because either the SNP was not available in 1000 Genomes imputation reference
Table 5. The 13 signals identified as having an associated 1000 Genomes-based imputed SNP reaching genome-wide significance where the best HapMap SNP did not, ordered by minor allele frequency group (<5% or ≥5) and the minor allele frequency of the 1000 Genomes SNP.

| Trait                          | HapMap-based Analysis | 1000 Genomes-based Analysis | BP Dist. | LD (r²) | Annotation |
|-------------------------------|-----------------------|-----------------------------|----------|---------|------------|
|                               | SNP                   | MAF                         | P        | SNP     | MAF        | P        | Beta | |
| Tumor necrosis factor-a       | rs10206283            | 0.289                       | 5.40E-03 | rs188141385 | 0.004       | 4.16E-10 | -2.101 | 218450 | 0.002 | Novel |
| Cl-                           | rs10262256            | 0.091                       | 2.21E-02 | rs2371549 | 0.005       | 5.38E-09 | -2.059 | 508371 | 0.001 | Novel |
| Alpha-1 globulin (%)          | rs10149388            | 0.054                       | 2.25E-04 | rs112635299 | 0.007       | 2.51E-12 | -1.891 | 371308 | 0.034 | Novel |
| Alpha-2 globulin (%)          | rs16959655            | 0.079                       | 1.58E-03 | rs181929163 | 0.011       | 1.57E-08 | 1.472  | 656607 | 0.004 | Novel |
| Total cholesterol             | rs17102098            | 0.021                       | 1.16E-05 | rs116435220 | 0.011       | 2.18E-08 | -1.243 | 149475 | 0.526 | Novel |
| Vitamin B12                   | rs3797617             | 0.146                       | 1.58E-03 | rs14626203 | 0.012       | 3.01E-08 | -1.38  | 566327 | 0.009 | Novel |
| Beta globulins (%)            | rs10516879            | 0.163                       | 1.51E-03 | rs28645201 | 0.022       | 1.22E-09 | 1.116  | 211623 | 0.032 | Novel |
| Dehydroepiandrosterone        | rs11761528            | 0.092                       | 9.67E-07 | rs34670419 | 0.028       | 2.07E-09 | -0.78  | 12033  | 0.263 | Known |
| Cortisol:DHEAS ratio          | rs10278040            | 0.045                       | 1.17E-05 | rs34670419 | 0.028       | 2.35E-08 | 0.721  | 10539  | 0.588 | Known |
| LDL cholesterol               | rs445925              | 0.114                       | 3.60E-05 | rs1005853 | 0.075       | 1.76E-09 | -0.526 | 2407   | 0.714 | Known |
| Beta Cryptoxanthin            | rs1464093             | 0.178                       | 5.05E-06 | rs75226183 | 0.087       | 1.69E-09 | -0.514 | 821919 | 0.049 | Novel |
| Creatine phosphokinase        | rs17112705            | 0.295                       | 6.92E-07 | rs61871700 | 0.282       | 4.18E-08 | 0.257  | 108933 | 0.78  | Known |
| Gamma-glutamyltransferase     | rs2017869             | 0.394                       | 7.94E-08 | rs2006227 | 0.386       | 1.70E-08 | 0.287  | 1553   | 0.973 | Known |

*P* - P-value derived after applying genomic control correction.
Details of the best HapMap SNP within a 2 MB window centred on the 1000 Genomes SNP are provided. Annotation “Novel” refers to signals not previously reported. Annotation “known” refers to signals not identified by HapMap but identified in the NHGRI GWAS catalogue.

doi:10.1371/journal.pone.0064343.t005
panel or it failed 1000 Genomes quality control based on the imputation-$r^2$ and converted to best-guess genotypes. PLINK was then used to obtain linkage disequilibrium estimates of the SNPs of interest within a given locus.

### Statistical thresholds

We report associations at two statistical thresholds. First, we used a $P$-value of $5 \times 10^{-11}$ to correct the usual threshold of $5 \times 10^{-8}$ for the ~100 traits analysed and the ~10 fold increase in signals tested (based on 10 million tests arising from 1000 Genomes imputation). This threshold is likely to be conservative given that the 10 million variants are not independent. There is also a Bayesian argument that reasonably presumes that more causal variants exist for more traits and that capturing more variants should result in more true positive signals of association. This argument, combined with the fact that many associations were known means we also report results at the traditional $5 \times 10^{-8}$.

### Known vs. novel Signals

We downloaded the catalogue of all association signals reaching genome-wide significance (available from the National Human Genome Research Institute (NHGRI), part of National Institutes of Health). We obtained lists of all known SNPs correlated with

| Trait | Index HM SNP | HM Uni $P$ | HM Multi $P$ | Index 1 KG SNP | 1 KG Uni $P$ | 1 KG Multi $P$ |
|-------|--------------|-----------|-------------|----------------|-------------|-------------|
| 90 K Protein | rs406652 | 2.33E-09 | 0.90 | rs28491433 | 4.29E-10 | 0.07 |
| Alpha-2 globulin (%) | rs2009999 | 2.79E-10 | 0.78 | rs2287997 | 1.01E-10 | 0.14 |
| Vitamin E alpha tocopherol | rs10401969 | 1.07E-08 | 0.80 | rs58542926 | 9.38E-09 | 0.58 |
| Beta carotene | rs6564851 | 1.26E-10 | 0.86 | rs12926540 | 4.73E-11 | 0.1625 |
| HDL cholesterol | rs1800775 | 1.98E-12 | 0.17 | rs711752 | 4.77E-13 | 0.0305 |
| Free thyroxine (FT4) | rs7212734 | 8.49E-09 | 0.04 | rs58926603 | 4.39E-09 | 0.0342 |
| Insulin-like growth factor bp-3 | rs10260816 | 2.07E-14 | 0.39 | rs71550311 | 6.16E-15 | 0.0774 |
| Interleukin-6R | rs8192284 | 8.84E-60 | 0.19 | rs12730935 | 4.87E-60 | 0.0882 |
| Lipoprotein a | rs10455872 | 5.06E-25 | 0.44 | rs55730499 | 2.34E-26 | 0.0097 |
| Lutein | rs11645428 | 5.96E-14 | 0.01 | rs9708919 | 4.03E-14 | 0.0072 |
| Macrophage inflammatory protein-1b | rs1015673 | 1.37E-23 | 0.002 | rs4796217 | 1.09E-21 | 0.2842 |
| Macrophage inflammatory protein-1b | rs1500004 | 9.33E-09 | 0.068 | rs113341849 | 1.37E-11 | 0.0003 |
| Soluble transferrin receptor | rs1242229 | 7.51E-09 | 0.71 | rs7940310 | 5.66E-09 | 0.4052 |
| Vitamin B6 | rs4654748 | 6.73E-09 | 0.20 | rs4654932 | 4.33E-09 | 0.1922 |

HM = HapMap, 1 KG = 1000 Genomes, Uni $P$ = $P$-value derived from univariable analysis after applying genomic control correction. Multi $P$ = $P$-value derived from multivariable analysis after applying genomic control correction.

doi:10.1371/journal.pone.0064343.t006

Figure 5. Locus zoom plots of the associations between HapMap and 1000 genomes imputed variants and alpha-1 globulin.

doi:10.1371/journal.pone.0064343.g005
\[ r^2 > 0.2 \] in Europeans with our index genome wide significant SNPs using the program SNAP (available from the BROAD Institute). We linked this list to phenotype-associated index SNPs using both the HapMap and 1000 Genomes based imputation results.

We classified a signal as known if our index SNP or an \[ r^2 > 0.8 \] proxy was associated with the same phenotype or a closely related phenotype (e.g. fatty acids and other lipids) in the NHGRI catalogue (at \( P < 5 \times 10^{-8} \)). We classified a locus as known if our index SNP or an \[ r^2 > 0.2 \] proxy was associated with the same phenotype in the NHGRI catalogue (\( P < 5 \times 10^{-8} \)).

As the NHGRI catalogue is not 100% complete, we also conducted literature searches using the name of the circulating factor and other key terms including “GWAS” or “Genome wide”.

### Does 1000 Genomes imputation identify stronger associations at loci identified by HapMap based imputation?

For all loci reaching genome-wide significance in the HapMap and 1000 Genomes based analysis we performed additional statistical tests to assess whether or not 1000 Genomes based imputation identifies stronger associations. We performed a multivariable test with dosages representing both the index HapMap and index 1000 Genomes SNP as independent variables (where the two index SNPs were different) in an additive genetic multi-variable SNP analysis. We used 1000 Genomes imputed dosages to represent SNPs identified by both HapMap and 1000 Genomes analyses in STATA. Where 1000 Genomes based dosages were not available we extracted the dosage from the HapMap imputation dataset. We compared the strength of association explained between univariable and multivariable SNP analyses.

### Replication and validation

For three of the putative novel associations we attempted to replicate associations in additional data. We used 476 and 529 individuals from the BLSA study [17] to test associations with TNF-alpha and vitamin B12, respectively. In addition, 232, 1554 and 4068 individuals from the TwinsUK study [18] were used to test associations with TNF-alpha, vitamin B12 and chlorine ion levels, respectively.

### Data availability

Genome wide summary statistics from all analyses are available from the authors on request. Please contact corresponding authors.

### Supporting Information

- **Figure S1** Distribution of SNP minor allele frequencies (MAFs) within imputation \( r^2 \) categories.
- **Figure S2** Distributions of the inverse normalised residual values of the 6 traits with evidence of low-frequency/large effect variants as captured by 1000 Genomes imputation.
- **Figure S3** A comparison of P-values when testing Alpha 1 globulin using overlapping SNPs present in both 1000 Genomes Phase 1 versions 1 and 3 on chromosome 14. Correlation coefficient = 0.931.
- **Table S1** The 93 circulating factors analysed.
- **Table S2** HapMap and 1000 Genomes based SNP counts per minor allele frequency (MAF) and imputation quality metric (\( r^2 \)) bin.

### Author Contributions

Conceived and designed the experiments: ARW TMF MNW. Performed the experiments: ARW JRBP TT HFZ TDS JBR. Contributed reagents/materials/analysis tools: DM. Wrote the paper: ARW TMF. Genotyped the InCHIANTI study: DGH JRG MAN ABS. Lead the InCHIANTI study: SB LF.

### References

1. Marchini J, Howie B (2010) Genotype imputation for genome-wide association studies. Nat Rev Genet 11: 499–511.

2. The International HapMap Consortium (2005) The International HapMap Project. Nature 426: 789–796.

3. The International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437: 1299–1320.

4. Altshuler DM, Gibbs RA, Peloso G, Pfeffer S, Hirschhorn JN, et al. (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467: 52–58.

5. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851–861.

6. The 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061–1073.

7. Ferrucci L, Bandinelli S, Bonanetti P, Di Iorio A, Macchi C, et al. (2000) Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 48: 1618–1625.

8. Melzer D, Perry JR, Hernandez D, Corsi AM, Stevens K, et al. (2008) A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 4: e1000072.

9. Freathy RM, Timpson NJ, Lavers DA, Pouta A, Ben-Shlomo Y, et al. (2008) Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 57: 1419–1426.
10. Perry JR, Ferrucci L, Bandinelli S, Guralnik J, Semba RD, et al. (2009) Circulating beta-carotene levels and type 2 diabetes—cause or effect? Diabetesologia 52: 2117–2121.

11. Perry JR, Weedon MN, Langenberg C, Jackson AU, Lyssenko V, et al. (2010) Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet 19: 535–544.

12. Rafiq S, Melzer D, Weedon MN, Lango H, Saxena R, et al. (2008) Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetesologia 51: 2205–2213.

13. Wu Y, McDade TW, Kuzawa CW, Borja J, Li Y, et al. (2012) Genome-wide association with C-reactive protein levels in CLHNS: evidence for the CRP and HNF1A loci and their interaction with exposure to a pathogenic environment. Inflammation 35: 574–583.

14. Ferrarotti I, Thom GA, Zorletto M, Ottaviani S, Imboden M, et al. (2012) Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax 67: 669–674.

15. Wood AR, Hernandez DG, Nalls MA, Yaghootkar H, Gibbs JR, et al. (2011) Allelic heterogeneity and more detailed analyses of known loci explain additional phenotypic variation and reveal complex patterns of association. Human molecular genetics 20: 4082–4092.

16. Major JM, Yu K, Wheeler W, Zhang H, Cornelis MC, et al. (2011) Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum Mol Genet 20: 3876–3883.

17. Terracciano A, Balaci L, Thayer J, Scally M, Kokinos S, et al. (2009) Variants of the serotonin transporter gene and NEO-PI-R Neuroticism: No association in the BLSA and SardiNIA samples. Am J Med Genet B Neuropsychiatr Genet 150B: 1070–1077.

18. Spector TD, Williams FM (2006) The UK Adult Twin Registry (TwinUK). Twin Res Hum Genet 9: 899–906.